Results 161 to 170 of about 26,895 (263)

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study. [PDF]

Circ Genom Precis Med
Remala S, Liang L, Shah AM, Buckley LF.
europepmc   +1 more source

Prescription patterns of SGLT2 inhibitors in patients admitted to a tertiary health service with heart failure with reduced ejection fraction: an opportunity to improve

Internal Medicine Journal, EarlyView.
Abstract Background Sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) improve symptoms, reduce hospitalisations and increase survival in patients with heart failure with reduced ejection fraction (HFrEF). This study evaluated SGLT2i prescribing compliance in hospitalised patients with HFrEF at an Australian tertiary hospital.
Salim Memon, Kanishaa Subhaharan, Tasnuba Ashan, Rogges Anandarajah, Nuwan Jasenthu Kankanamage   +4 more
wiley   +1 more source

SGLT2 Inhibitor-Associated Changes in Urinary Volatile Organic Compounds in Diabetic Kidney Disease: A Comprehensive Study. [PDF]

Nephrology (Carlton)
Hara R, Yamahara H, Hirakawa Y, Hashiba T, Keying H, Tabata H, Nangaku M.   +6 more
europepmc   +1 more source

Prediction of incident heart failure in type 2 diabetes mellitus: Rationale and design of the DM‐HEART study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin, Yen‐Wen Wu, Sung‐Chen Liu, Chung‐Ming Tu, Heng‐Hsu Lin, Yi‐Fu Lin, Hao‐Yun Chang, Ming‐Nan Chien, Chih‐Yuan Wang, Chung‐Lieh Hung   +9 more
wiley   +1 more source

Diabetic Ketoacidosis Associated With Painless Thyroiditis in a Patient Treated With an SGLT2 Inhibitor. [PDF]

Case Rep Endocrinol
Aotani R, Ohkuma T, Oshiro A, Okamura K, Ago T.   +4 more
europepmc   +1 more source

Time in range during caloric restriction in type 2 diabetes with obesity

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction To evaluate glycemic changes during caloric restriction with continuous glucose monitoring (CGM)‐derived time in range (TIR) in individuals with type 2 diabetes and obesity. Materials and Methods This 12‐week single‐arm intervention consisted of 6 weeks of home‐delivered meals (800–1,200 kcal/day), followed by 6 weeks of self ...
Jinyoung Kim, Joonyub Lee, Mee Kyoung Kim, Oakkee Hong, Young Na, Su‐Jeong Park, Yoon‐Ju Song, Ki‐Hyun Baek, Ki‐Ho Song, Hyuk‐Sang Kwon   +9 more
wiley   +1 more source

Disentangling Uric Acid and Renal Pathways in SGLT2 Inhibitor Effects After Acute Myocardial Infarction: A Retrospective Mediation Analysis. [PDF]

Biomedicines
Suciu IM, Muntean C, Gaiță L, Mateoc-Sîrb T, Vlad DC, Timar B, Gaiță D.   +6 more
europepmc   +1 more source

Cholesterol accumulation in monocytes is associated with the severity of diabetic complications and the efficacy of glycemic control interventions in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This study reveals that monocyte cholesterol accumulation correlates with the severity of diabetic complications and predicts post‐discharge glycemic deterioration. These findings suggest that monocytic cholesterol serves as a novel translational biomarker reflecting ‘metabolic memory’ and therapeutic resistance in patients with type 2 diabetes ...
Hideyuki Okuma, Takahiro Tsutsumi, Asako Miyazaki, Kyoichiro Tsuchiya   +3 more
wiley   +1 more source

Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease.

JAMA Netw Open
Pestka DL, Murphy D, Kaplan AN, Taylor BC, Huynh P, Rechtzigel JA, Kjos S, Ellich LM, Atwood M, Polsfuss BA, Thomas AR, Lee JY, Ishani A.   +12 more
europepmc   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source